TY - JOUR
T1 - The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks
T2 - a review of two placebo-controlled phase II trials
AU - Tfelt-Hansen, Peer C
AU - Olesen, Jes
PY - 2012
Y1 - 2012
N2 - Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P
AB - Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P
U2 - 10.1007/s10194-012-0428-7
DO - 10.1007/s10194-012-0428-7
M3 - Journal article
C2 - 22430431
VL - 13
SP - 271
EP - 275
JO - Journal of Headache and Pain
JF - Journal of Headache and Pain
SN - 1129-2369
IS - 4
ER -